Erin Schenk, MD, PhD

Assistant Professor, Medicine-Medical Oncology


FacultyPhoto
Medical School
  • MD, Mayo Medical School (2011)
Graduate School
  • PhD, Mayo Graduate School (2011)
Residency
  • College of Medicine, Mayo Clinic Program, Internal Medicine (2014)
Fellowships
  • College of Medicine, Mayo Clinic (Rochester) Program, Hematology and Oncology (2018)
Languages
English
Department
Medicine-Medical Oncology

Professional Titles

  • Assistant Professor of Medicine, Division of Medical Oncology

Recognitions

  • Finalist, Immuno-Oncology Young Investigators' Forum (2018)
    Houston, TX
  • Outstanding Fellow Award, Highest Rated and Top Abstract, Minnesota Society of Clinical Oncology (2018)
    Minneapolis, MN
  • International Association for the Study of Lung Cancer (IASLC) Academy Award, IASLC (2018)
    Toronto, Canada
  • IASLC Academy Award, IASLC (2017)
    Yokohama, Japan
  • Paul Calabresi Career Development Award for Clinical Oncology K12, University of Colorado Cancer Center (2019)
  • LUNGevity Career Development Award, LUNGevity (2021)
    This research grant provides significant funding for 3 years to promising early career investigators engaged in lung cancer research.
  • Translational Research Scholar, School of Medicine, University of Colorado (2022)
    The Translational Research Scholar Program aims to foster translational research among the School’s early career faculty, facilitating the pursuit of new lines of exploration and elevating and expanding the scope of their translational research.
  • Member, ASCO Expert Panel Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations, ASCO (2022)
    https://ascopubs.org/doi/10.1200/JCO.22.02121
  • Member, ASCO Expert Panel Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations, ASCO (2022)
    https://ascopubs.org/doi/10.1200/JCO.22.02124

Research Interests

My laboratory studies the lung cancer tumor microenvironment, a diverse collection of cell types that can be found in and around lung tumors. We are focused on the immune cells within the tumor and how specific subtypes can contribute to treatment resistance. Ultimately, we hope to use our findings to improve therapy for patients with lung cancer.

Publications

  • Patil T, Gao D, Watson A, Sakamoto M, Nie Y, Gibson A, Dean ML, Yoder BA, Miller E, Stalker M, Aisner DL, Bunn PA, Schenk EL, Marmarelis ME, Bennati C, Navani V, Zhang Y, Camidge DR. The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations. Lung Cancer. 2024 Nov 25;199:108040. [Epub ahead of print] PubMed PMID: 39615411
  • Watson AS, Krause HB, Elliott A, Farrell A, Liu SV, Ma PC, VanderWalde A, Sledge GW, Spetzler D, Schenk EL, Camidge DR. Use of Oncogene Overlap by Tissue-Based Next-Generation Sequencing to Explore the Mutational Landscape and Survival Impact of HER2, KRAS and MET Copy-Number Gain in Nonsmall Cell Lung Cancer. Clin Lung Cancer. 2024 Dec;25(8):712-722.e1. PubMed PMID: 39384504
  • Blakely CM, Urisman A, Gubens MA, Mulvey CK, Allen GM, Shiboski SC, Rotow JK, Chakrabarti T, Kerr DL, Aredo JV, Bacaltos B, Gee M, Tan L, Jones KD, Devine WP, Doebele RC, Aisner DL, Patil T, Schenk EL, Bivona TG, Riess JW, Coleman M, Kratz JR, Jablons DM. Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study. J Clin Oncol. 2024 Sep 10;42(26):3105-3114. PubMed PMID: 39028931
  • Sigafoos AN, Tolosa EJ, Carr RM, Fernandez-Barrena MG, Almada LL, Pease DR, Hogenson TL, Raja Arul GL, Mousavi F, Sen S, Vera RE, Marks DL, Flores LF, LaRue-Nolan KC, Wu C, Bamlet WR, Vrabel AM, Sicotte H, Schenk EL, Smyrk TC, Zhang L, Rabe KG, Oberg AL, Zaphiropoulos PG, Chevet E, Graham RP, Hagen CE, di Magliano MP, Elsawa SF, Pin CL, Mao J, McWilliams RR, Fernandez-Zapico ME. KRAS Promotes GLI2-Dependent Transcription during Pancreatic Carcinogenesis. Cancer Res Commun. 2024 Jul 1;4(7):1677-1689. PubMed PMID: 38896052
  • Tsui DCC, Holt DE, Patil T, Staley A, Gao D, Kavanagh BD, Schenk EL, Rusthoven CG, Camidge DR. The Role of Local Therapy for Oligo-Progressive Disease in Oncogene-Addicted Non-Small-Cell Lung Cancer. Adv Radiat Oncol. 2024 Jul;9(7):101516. PubMed PMID: 38868503

Professional Memberships

  • IASLC, Member
  • American Society of Clinical Oncology (ASCO), Member
  • American Association for Cancer Research (AACR), Member

Practice Locations

UCHealth Lung Cancer Clinic - Anschutz Medical Campus
1665 Aurora Ct
Anschutz Cancer Pavilion
Aurora, CO 80045
720-848-0300

Hospital Affiliation
  • University of Colorado Hospital

Center Affiliations

Specialty Information

Specialties
  • Medical Oncology, Board Certification (2018)
  • Hematology, Board Certification (2018)
  • Internal Medicine, Board Certification (2014)
Conditions & Treatments
  • Cancers - Lung Cancer
  • Cancers
Public Speaking
Yes